IL6 and acute respiratory distress syndrome: A retrospective study of patients with chronic cardiovascular diseases and confirmed COVID-19 disease who were hospitalized in both therapeutic and intensive care units confirmed that circulating levels of several inflammatory markers, including IL-6, were significantly lower in patients who took RAASI; however, this treatment did not significantly affect such unfavorable outcomes as acute respiratory distress syndrome, sepsis, and death [27].